This Monster Growth Stock Is Up 167% in the Past Year and Disrupting the Healthcare Space

Hims & Hers (HIMS) is experiencing rapid growth in the telehealth market through its direct-to-consumer subscription model, with revenue expected to reach $2.3 billion in 2025 and a long-term goal of $6.5 billion by 2030; the company is expanding its offerings, including a partnership with Novo Nordisk for Wegovy, and pursuing international growth through the acquisition of Zava in Europe. Despite a high P/E ratio of 79, analysts believe Hims & Hers could grow into its valuation if it maintains its growth trajectory and achieves its long-term revenue targets, but the stock may be overvalued if growth slows.

Analysis

Hims & Hers (NYSE: HIMS) is demonstrating significant market penetration in the telehealth sector through its direct-to-consumer, insurance-bypassing subscription model, delivering medications for common health concerns. The company has achieved substantial growth, evidenced by a 449% stock increase since its IPO, a 158% rise in the past year, trailing-12-month revenue of $1.78 billion, and a 111% year-over-year sales growth in the last quarter. Strategic expansion includes partnering with Novo Nordisk (NYSE: NVO) for the weight loss drug Wegovy, and a proposed acquisition of European competitor Zava, which adds 1.3 million active customers. Hims & Hers, with 2.4 million current active customers, targets revenues of at least $2.3 billion in 2025 and $6.5 billion by 2030. Despite a high current price-to-earnings (P/E) ratio of 79, its robust revenue growth and 77% gross profit margin suggest potential to grow into this valuation, possibly achieving a P/E between 9.5 and 12 by 2030 if revenue targets and a 20% net profit margin are realized; however, sustained high-level execution is critical for this outcome.

Key Decisions for Investors

• Investors may find Hims & Hers attractive due to its disruptive direct-to-consumer model, rapid revenue growth, and strategic expansions into new products like Wegovy and international markets via the Zava acquisition.
• However, the current high P/E ratio of 79 necessitates careful consideration, as the stock's valuation heavily relies on achieving ambitious long-term growth targets and successful execution of its expansion plans; failure to maintain this momentum could expose the stock as overvalued.
• Close monitoring of customer acquisition trends, revenue growth sustainability, the integration progress of Zava, and the market reception of new offerings like Wegovy is essential for assessing ongoing investment viability.